Bristol-Myers Squibb Company
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The compan…
Drug Manufacturers - General
US, New York [HQ]
FA
Fundamental Analysis · Most Recent Quarter
A dedicated fundamental analysis might help you to get a quick overview
of the
financial stability. It is important to understand the
FA Algorithm
and the criterias before valuing it as a top-tier resource.
1
Financial Health
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Current Ratio | -22.20 | 1.11 | 1.43 | |
| Debt/Assets | n.A. | n.A. | n.A. | |
| Debt/Equity | n.A. | n.A. | n.A. | |
| Net Debt/EBITDA | 49.49 | 10.81 | 7.23 | |
| Naive Interpretation | member | |||
2
Per Share
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Book Value | -43.86 | 8.15 | 14.52 | |
| Cash | -21.10 | 4.78 | 6.06 | |
| Capex | 13.77 | -0.14 | -0.16 | |
| Free Cash Flow | -34.85 | 1.26 | 1.93 | |
| Revenue | 3.59 | 5.87 | 5.66 | |
| Naive Interpretation | member | |||
3
Profitability
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Gross Margin | -1.04 | 0.75 | 0.76 | |
| Operating Margin | 122.35 | 0.33 | 0.15 | |
| ROA | 549.56 | -0.12 | 0.02 | |
| ROE | 1106.46 | -0.72 | 0.06 | |
| ROIC | 116.64 | 0.05 | 0.03 | |
| Naive Interpretation | member | |||
4
Valuation
The "Valuation Entry" for the Focus of BMY is permitted for members.
5
Growth
The "Growth Entry" for the Focus of BMY is permitted for members.
6
Leverage & Liquidity